EVMN
Evommune, Inc.Investor Moves
News
businesswire.comEvommune Reports First Quarter 2026 Financial Results and Provides Business Highlightsbusinesswire.comMay 7
seekingalpha.comEvommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcriptseekingalpha.comApr 14
businesswire.comEvommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migrainebusinesswire.comApr 6
defenseworld.netCapricorn Fund Managers Ltd Acquires Shares of 60,000 Evommune, Inc. $EVMNdefenseworld.netApr 6
